Tom Powles, MIBC
Tom Powles/X

Tom Powles: Promising Data on Carboplatin/Gemcitabine in M1 Bladder Cancer from EVP

Tom Powles, Professor at the University of London, shared a post on X:

“The most robust data post EVP in M1 bladder cancer by Michal Sternschuss Carboplatin/gem was the commonest regimen.
Results showed higher RRs than expected (50%) PFS =4.5 months & OS =11 months are good. 1st line gem/carbo OS was ~10 months
previously?”

Tom Powles